Contract Pharma Staff11.12.20
Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics, has appointed Bin Zhang as chief executive officer.
Zhang served two months as Interim CEO before this formal appointment by the board to CEO. He will report to Mr. Li Li, founder and chairman of the Board for Shenzhen Hepalink Pharmaceutical Group Co. Ltd. and member of the Board for Cytovance.
Zhang has been with Cytovance as a member of the Board of Directors since 2018. In this role as CEO, he will provide oversight in the implementation of the company’s business strategies in the innovative drug development and contract manufacturing market.
“It is an honor to work with the talented Cytovance team more closely than my board member role,” Zhang commented. “Cytovance has made tremendous progress since the Hepalink acquisition in 2015. With the trust of our clients, the hard work of all Cytovance staff and the additional investment made by Hepalink after the acquisition, we have strengthened our core services in both capacity and scope and entered into commercial stage manufacture. The board of Cytovance and Hepalink are both committed to make additional investments in Cytovance to better serve our clients and ultimately to bring well-being to patients around the world.”
Zhang will also continue to serve as the financial controller for Hepalink where his primary responsibilities include participating in decision-marking in respect of business operation strategies and overseeing the business strategy and financial activities of Hepalink. He holds a Master of Business Administration and serves on the board of other subsidiaries within Hepalink.
Zhang served two months as Interim CEO before this formal appointment by the board to CEO. He will report to Mr. Li Li, founder and chairman of the Board for Shenzhen Hepalink Pharmaceutical Group Co. Ltd. and member of the Board for Cytovance.
Zhang has been with Cytovance as a member of the Board of Directors since 2018. In this role as CEO, he will provide oversight in the implementation of the company’s business strategies in the innovative drug development and contract manufacturing market.
“It is an honor to work with the talented Cytovance team more closely than my board member role,” Zhang commented. “Cytovance has made tremendous progress since the Hepalink acquisition in 2015. With the trust of our clients, the hard work of all Cytovance staff and the additional investment made by Hepalink after the acquisition, we have strengthened our core services in both capacity and scope and entered into commercial stage manufacture. The board of Cytovance and Hepalink are both committed to make additional investments in Cytovance to better serve our clients and ultimately to bring well-being to patients around the world.”
Zhang will also continue to serve as the financial controller for Hepalink where his primary responsibilities include participating in decision-marking in respect of business operation strategies and overseeing the business strategy and financial activities of Hepalink. He holds a Master of Business Administration and serves on the board of other subsidiaries within Hepalink.
